Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Fulvio Spirito"'
Autor:
Giuseppe Losurdo, R. Lovero, Rosa Federica La Fortezza, M. Gentile, Angelo Andriulli, Fulvio Spirito, Alfredo Di Leo
Publikováno v:
European journal of clinical investigationREFERENCES.
Background Acute obstructive colorectal cancer requires prompt decompression commonly by emergency surgery (ES). However, self-expanding metal stents (SEMS) have been increasingly used as a bridge-to-surgery (BTS) strategy. Materials and methods In a
Autor:
A. Di Leo, Giuseppe Losurdo, R. Lovero, R.F. La Fortezza, M. Principi, Fulvio Spirito, M. Gentile, Angelo Andriulli
Publikováno v:
Digestive and Liver Disease. 52:S172
Autor:
Angelo Andriulli, Grazia Anna Niro, Grazia Napolitano, Rosario Forlano, Fulvio Spirito, Alberto Pilotto, Maria Rosa Valvano, Silvano Loperfido
Publikováno v:
The American Journal of Gastroenterology. 102:1781-1788
OBJECTIVES: To provide health-care providers, patients, and physicians with an exhaustive assessment of prospective studies on rates of complications and fatalities associated with endoscopic retrograde cholangiopancreatography (ERCP). METHODS: We se
Autor:
Fulvio Spirito, Angelo Andriulli, D. Bacca, Mario R. Romano, Gaetano Scotto, Marcello Persico, Fernando Sogari, G.L. Ricci, Nicola Minerva, Mauro Annese, Alessandra Mangia, Francesco Vinelli, Rosanna Santoro, Franco Zechini, Vito Carretta
Publikováno v:
New England Journal of Medicine. 352:2609-2617
background We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks. methods A total of 283 patients were randomly assi
Autor:
Giovambattista Forte, Angelo Andriulli, Vittorio Terruzzi, Virginia Festa, Maria Rita Magnolia, Francesco Perri, Fabio Monica, Pietro Leo, Enrico Ciliberto, Angelo Belmonte, Michele Silla, Fulvio Spirito, L. Solmi, Giorgio Marenco, Silvano Loperfido, Antonio Di Sabatino
Publikováno v:
Clinical Gastroenterology and Hepatology. 2:713-718
Background & Aims: It still is debated whether post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis can be prevented by administering either somatostatin or gabexate mesylate. The aim of the study is to assess the efficacy of a 6.5
Autor:
Mauro Annese, Vito Carretta, Alessandra Mangia, M. Cela, Fulvio Spirito, Marisa Piattelli, Nicola Minerva, Gioacchino Leandro, Rosanna Santoro, Angelo Andriulli, D. Bacca, Francesco Ventrella
Publikováno v:
Journal of Hepatology. 37:109-116
The aim of the present, open-labelled, controlled study was to determine whether 5 MU of interferon (IFN) alpha 2b combined with a standard dose of ribavirin might increase the rate of viral clearance in all patients with chronic HCV hepatitis or at
Autor:
Giorgio Verme, Franco Macor, A. Solinas, Mario Rizzetto, Angelo Andriulli, Claudia Spezia, Carlo Donada, Vittorio Gallo, Valter Donadon, Alessandra Mangia, Giorgio Maria Saracco, E. Borghesio, Livio Chiandussi, Fulvio Spirito, Pietro Mesina
Publikováno v:
Journal of Hepatology. 27:56-62
Background/Aims: To examine the effect of prolonged treatment with different doses of interferon α-2b on the relapse rate in patients with chronic hepatitis C. Methods: One hundred and seventy-one patients with non-cirrhotic chronic hepatitis C were
Autor:
Francesco Perri, Antonio Merla, M. Gentile, Daniela Scimeca, Angelo Andriulli, Fulvio Spirito, Fulvia Terracciano
Publikováno v:
Endoscopy. 43
Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial
Autor:
Giuseppe Cristofaro, Giuseppe Montalto, D. Bacca, Francesco Vinelli, Raffaele Cozzolongo, G.L. Ricci, Angelo Andriulli, Leonardo Mottola, Mario R. Romano, Nicola Minerva, Fulvio Spirito, Gaetano Scotto, Vito Carretta, Alessandra Mangia
It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c318ebec2b6d1d50877a8b937ff990
http://hdl.handle.net/11573/87790
http://hdl.handle.net/11573/87790
Autor:
M. Piattelli, Giovanni De Maio, Valerio Pazienza, Alessandra Mangia, Fulvio Spirito, Angelo Andriulli, Davide Festi, D. Bacca, M. Cela, G.L. Ricci, Marcello Persico, Nicola Minerva, Vincenzo Guadagnino, Mauro Annese, Vito Carretta, D. Conte
We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginterferon (PEG-IFN) alpha-2a or conventional IFN alpha-2a would improve sustained virological response (SVR) rates over dual therapy with IFN alpha-2a an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e60c68e0835d5cf96e8e9e179884f8f2
http://hdl.handle.net/11386/3138191
http://hdl.handle.net/11386/3138191